- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 1 | HKEx | ||
| 24.06. | China's CARsgen Slides for Second Day on Hefty Price Tag for World's First Solid Tumor CAR-T Therapy | 3 | Yicai Global | ||
| 22.06. | CARsgen makes history as China approves world's first CAR-T therapy for solid tumors | 1 | FiercePharma | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.06. | CARSgen bags world-first approval for solid tumour CAR-T | 2 | pharmaphorum | ||
| 22.06. | CARsgen's Solid-Tumor CAR-T Therapy Nears China Approval, a Global First | 1 | Yicai Global | ||
| 22.06. | CARSGEN-B (02171): INSIDE INFORMATION ANNOUNCEMENT - THE NMPA APPROVES THE NEW DRUG APPLICATION FOR THE CLAUDIN18.2 CAR T-CELL THERAPY PRODUCT SATRICABTAGENE ... | 1 | HKEx | ||
| 15.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT0596 AND CT1190B AT 2026 EHA ANNUAL CONGRESS | 1 | HKEx | ||
| 01.06. | CARsgen Therapeutics: Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting | 76 | PR Newswire | SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 01.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON SATRI-CEL AT THE 2026 ASCO ANNUAL MEETING | 1 | HKEx | ||
| 26.05. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.05. | CARSGEN-B (02171): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 4 | HKEx | ||
| 22.05. | CARSGEN-B (02171): NINTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 5 | HKEx | ||
| 22.05. | CARSGEN-B (02171): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2026 | - | HKEx | ||
| 22.05. | CARSGEN-B (02171): CLARIFICATION ANNOUNCEMENT | 1 | HKEx | ||
| 15.05. | CARSGEN-B (02171): PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 27.04. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT0596 AND CT1190B ACCEPTED FOR POSTER PRESENTATION AT 2026 EHA ANNUAL CONGRESS | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 114,76 | 0,00 % | KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug | ||
| QIAGEN | 34,075 | -1,59 % | QIAGEN NV - Stabilität als strategischer Anker | ||
| BIONTECH | 83,50 | -1,24 % | Burrys Short-Angriff bei Micron Technologies, BioNTechs Radikalkur und Strategic Resources - ein noch stiller Rohstoff-Player! | Während der unglaubliche Boom rund um die Künstliche Intelligenz gigantische Gewinne verspricht, ziehen erste dunkle Wolken am Horizont auf. Prominente Investoren wetten plötzlich gegen die noch, bzw.... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,52 | +0,02 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| IMMUNOVANT | 38,600 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,060 | -0,17 % | What's Going on with Vera Therapeutics Stock on Monday? | ||
| PRAXIS PRECISION MEDICINES | 313,04 | -0,15 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BEAM THERAPEUTICS | 35,330 | +0,03 % | Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More | ||
| ABSCI | 11,525 | -0,13 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,010 | 0,00 % | Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? | ||
| SUMMIT THERAPEUTICS | 15,940 | +0,06 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| DYNE THERAPEUTICS | 22,845 | +0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| ERASCA | 18,860 | +0,05 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,880 | 0,00 % | Leerink raises Moonlake stock price target on HS drug data |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.